Genta Appoints Senior Pharmaceutical Industry Executive, William P. Keane, as Chief Financial Officer Seasoned Leader with Experience at Bristol-Myers Squibb, Warner-Lambert, and Novartis to Lead Financial Operations and Strategic Planning
BERKELEY HEIGHTS, N.J., Oct 28, 2002 /PRNewswire-FirstCall via COMTEX/ -- Genta
Incorporated (Nasdaq: GNTA) announces the appointment of William P. Keane as
Vice-President and Chief Financial Officer (CFO). Mr. Keane brings more than
twenty-five years of experience in finance and management within the
pharmaceutical industry to Genta. Mr. Keane will lead the company's Finance,
Strategic Planning, and Information Technology (IT) groups at Genta, where he
will report to the Chief Executive Officer.
Mr. Keane most recently served as Vice President of Sourcing, Strategy, and
Operations Effectiveness at Bristol Myers Squibb, Inc. In this position, he
oversaw the Technical Operations unit that included Manufacturing, Quality,
Facilities, and Engineering. Mr. Keane was also responsible for the integration
of the Manufacturing and Quality divisions of DuPont Pharmaceuticals following
its acquisition by Bristol-Myers Squibb. From 2000 to 2001, he served as CFO of
Covance Biotechnology Services Inc., where he worked towards the divestiture of
that company from Covance Inc. From 1997 to 2000, Mr. Keane served as
Vice-President of Finance within the Global Manufacturing group at
Warner-Lambert/Pfizer, where he led the Finance and Systems groups that
supported the Global Manufacturing and Quality functions of the Pharmaceuticals
Sector. From 1985 to 1997, he held positions of increasing responsibility in
Finance and Operations at Ciba-Geigy/Novartis. His positions included leading
the Finance, IT, Business Development, and Administration functions of the U.K.
pharmaceuticals business of Novartis AG. Mr. Keane also participated in the
merger of Ciba-Geigy with Sandoz to form Novartis.
Mr. Keane commented: "I'm very pleased to be joining the extraordinarily
experienced group of senior managers at Genta, each of whom has established
strong track records of success in the pharmaceutical industry."
"We are delighted to welcome Bill Keane onto our team, an individual who
combines strong financial strength with extensive operational experience in the
pharmaceutical sector," commented Dr. Raymond P. Warrell, Genta's Chairman and
Chief Executive Officer. "Bill's background in strategic planning, IT
implementation, and financial management will be a tremendous asset to the
Company as we begin commercialization of our product portfolio."
About Genta
Genta Incorporated is a biopharmaceutical company with a diversified product
portfolio that is focused on anticancer therapy. The Company's research platform
is anchored by oligonucleotide chemistry, particularly applications of antisense
and decoy aptamer technology. Genasense(TM), the Company's lead compound, is
currently undergoing late-stage, Phase 3 clinical testing in several clinical
indications. Genta's pipeline also comprises a portfolio of small molecules,
including gallium-containing compounds and Androgenics compounds for prostate
cancer. For more information about Genta, please visit our website at:
genta.com. |
